STAT+: FDA staff and peptide enthusiasts set to clash at advisory panel

FDA advisers are set to consider whether allowing compounding pharmacies to offer largely unproven peptides is a safer bet than the gray-market versions now in use. ...
이 뉴스, 어떠셨어요?
탭 한 번으로 반응 · 로그인 불필요